Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arena Pharmaceuticals (ARNA)

Arena Pharmaceuticals (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,436,443
  • Shares Outstanding, K 49,825
  • Annual Sales, $ 17,970 K
  • Annual Income, $ -29,400 K
  • 60-Month Beta 1.53
  • Price/Sales 131.20
  • Price/Cash Flow N/A
  • Price/Book 1.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -1.36
  • Number of Estimates 2
  • High Estimate -1.31
  • Low Estimate -1.40
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -94.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.31 +11.28%
on 10/04/19
52.73 -6.49%
on 09/18/19
-3.02 (-5.77%)
since 09/16/19
3-Month
44.31 +11.28%
on 10/04/19
64.48 -23.53%
on 08/01/19
-12.46 (-20.17%)
since 07/16/19
52-Week
31.97 +54.24%
on 11/14/18
64.48 -23.53%
on 08/01/19
+7.79 (+18.76%)
since 10/16/18

Most Recent Stories

More News
Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator,...

ARNA : 49.31 (+0.84%)
First Week of December 20th Options Trading For Arena Pharmaceuticals (ARNA)

Investors in Arena Pharmaceuticals Inc saw new options become available this week, for the December 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay,...

ARNA : 49.31 (+0.84%)
Arena Pharmaceuticals to Present at the Cantor Global Healthcare Conference on October 2

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, President and Chief Executive Officer of Arena, will present a corporate update at the Cantor Global Healthcare Conference...

ARNA : 49.31 (+0.84%)
Arena Pharmaceuticals to Present New Preclinical Atopic Dermatitis Data for Etrasimod at the European Society for Dermatologic Research Annual Meeting

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new preclinical data for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in development...

ARNA : 49.31 (+0.84%)
United Therapeutics' Trevyent NDA for PAH Accepted by FDA

United Therapeutics (UTHR) announces acceptance of Trevyent NDA by the FDA for pulmonary arterial hypertension.

MDT : 108.50 (+0.29%)
MNKD : 1.27 (unch)
ARNA : 49.31 (+0.84%)
UTHR : 81.76 (-0.26%)
Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterology & Motility NeuroGASTRO 2019 Meeting

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor...

ARNA : 49.31 (+0.84%)
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences:

WFC : 49.59 (-1.04%)
ARNA : 49.31 (+0.84%)
Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.

BGNE : 126.52 (+1.36%)
ARNA : 49.31 (+0.84%)
UTHR : 81.76 (-0.26%)
GH : 65.02 (-1.00%)
Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and Olorinab CAPTIVATE Trials

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2019.

ARNA : 49.31 (+0.84%)
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y

United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.

LLY : 107.95 (-1.60%)
NVS : 87.00 (+0.35%)
ARNA : 49.31 (+0.84%)
UTHR : 81.76 (-0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade ARNA with:

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Key Turning Points

2nd Resistance Point 50.14
1st Resistance Point 49.72
Last Price 49.31
1st Support Level 48.77
2nd Support Level 48.24

See More

52-Week High 64.48
Fibonacci 61.8% 52.06
Last Price 49.31
Fibonacci 50% 48.23
Fibonacci 38.2% 44.39
52-Week Low 31.97

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar